The improvement in diagnostic assay performance observed for CA15-3 may also be applicable for other glycoprotein cancer biomarkers that express Neu5Gc, such as CA125, prostate-specific antigen, human epididymis protein 4 and carcinoembryonic antigen. This evidence concerns the gene CEACAM5 and cancer.